KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Acadia Pharmaceuticals (ACAD) Net Income: 2009-2024

Historic Net Income for Acadia Pharmaceuticals (ACAD) over the last 16 years, with Dec 2024 value amounting to $226.5 million.

  • Acadia Pharmaceuticals' Net Income rose 119.14% to $71.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $261.2 million, marking a year-over-year increase of 103.33%. This contributed to the annual value of $226.5 million for FY2024, which is 469.20% up from last year.
  • Acadia Pharmaceuticals' Net Income amounted to $226.5 million in FY2024, which was up 469.20% from -$61.3 million recorded in FY2023.
  • Acadia Pharmaceuticals' 5-year Net Income high stood at $226.5 million for FY2024, and its period low was -$281.6 million during FY2020.
  • Moreover, its 3-year median value for Net Income was -$61.3 million (2023), whereas its average is -$17.0 million.
  • In the last 5 years, Acadia Pharmaceuticals' Net Income declined by 28.66% in 2022 and then spiked by 469.20% in 2024.
  • Yearly analysis of 5 years shows Acadia Pharmaceuticals' Net Income stood at -$281.6 million in 2020, then soared by 40.38% to -$167.9 million in 2021, then dropped by 28.66% to -$216.0 million in 2022, then soared by 71.60% to -$61.3 million in 2023, then soared by 469.20% to $226.5 million in 2024.